Brooks Laboratories (BOM:533543) Cyclically Adjusted Revenue per Share: ₹38.54 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:533543 Brooks Laboratories Ltd BOM:533543
59 GF Score
Price ₹69.50
GF Value ₹114.08
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Brooks Laboratories Cyclically Adjusted Revenue per Share?

Brooks Laboratories BOM:533543 +4.45% 59 Cyclically Adjusted Revenue per Share is ₹38.54 as of Jun. 2026. GuruFocus rates BOM:533543 with a GF Score™ of 59/100 and a GF Value™ of ₹114.08 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Brooks Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹7.838. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹38.54 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Brooks Laboratories's average Cyclically Adjusted Revenue Growth Rate was -4.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Brooks Laboratories was -4.20% per year. The lowest was -5.40% per year. And the median was -5.00% per year.

As of today (2026-08-29), Brooks Laboratories's current stock price is ₹69.50. Brooks Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹38.54. Brooks Laboratories's Cyclically Adjusted PS Ratio of today is 1.80.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Brooks Laboratories was 4.73. The lowest was 0.59. And the median was 2.11.


Brooks Laboratories  (BOM:533543) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Brooks Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=69.50/38.54
=1.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Brooks Laboratories was 4.73. The lowest was 0.59. And the median was 2.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Brooks Laboratories Cyclically Adjusted Revenue per Share Related Terms


Brooks Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Brooks Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brooks Laboratories Cyclically Adjusted Revenue per Share Chart

Brooks Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.97 45.28 42.90 40.21 38.28

Brooks Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.16 39.93 39.05 38.28 38.54

BOM:533543 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brooks Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Brooks Laboratories's Cyclically Adjusted PS Ratio falls into.


BOM:533543
59GF Score
Brooks Laboratories Ltd BOM:533543
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brooks Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brooks Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.838/167.3573*167.3573
=7.838

Current CPI (Jun. 2026) = 167.3573.

Brooks Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.938 105.961 10.958
201612 7.281 105.196 11.583
201703 7.313 105.196 11.634
201706 3.650 107.109 5.703
201709 6.728 109.021 10.328
201712 10.648 109.404 16.288
201803 7.418 109.786 11.308
201806 5.434 111.317 8.170
201809 7.217 115.142 10.490
201812 7.727 115.142 11.231
201903 7.732 118.202 10.947
201906 10.306 120.880 14.269
201909 6.971 123.175 9.471
201912 9.775 126.235 12.959
202003 7.324 124.705 9.829
202006 5.003 127.000 6.593
202009 11.617 130.118 14.942
202012 8.515 130.889 10.887
202103 5.245 131.771 6.661
202106 8.837 134.084 11.030
202109 8.668 135.847 10.679
202112 7.630 138.161 9.242
202203 11.044 138.822 13.314
202206 9.338 142.347 10.979
202209 7.248 144.661 8.385
202212 6.190 145.763 7.107
202303 4.848 146.865 5.524
202306 6.358 150.280 7.080
202309 8.912 151.492 9.845
202312 8.466 152.924 9.265
202403 6.725 153.035 7.354
202406 6.985 155.789 7.504
202409 7.921 157.882 8.396
202412 7.890 158.323 8.340
202503 8.636 157.552 9.173
202506 8.650 159.755 9.062
202509 7.967 162.289 8.216
202512 5.634 163.281 5.775
202603 6.900 164.272 7.030
202606 7.838 167.357 7.838

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹38.54 mean?
Brooks Laboratories (BOM:533543) has a Cyclically Adjusted Revenue per Share of ₹38.54 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Brooks Laboratories and its competitors.
Is Brooks Laboratories' Cyclically Adjusted Revenue per Share too high?
Brooks Laboratories' current Cyclically Adjusted Revenue per Share is ₹38.54. Overall, Brooks Laboratories has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS?
Brooks Laboratories' Cyclically Adjusted Revenue per Share of ₹38.54 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Brooks Laboratories and its competitors. Brooks Laboratories's current Cyclically Adjusted Revenue per Share is ₹38.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹114.08, compared to a current price of ₹69.50 — trading 39.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹38.54. Brooks Laboratories' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Cyclically Adjusted Revenue per Share is ₹38.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brooks Laboratories (BOM:533543) Overvalued in 2026?

Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued. The current stock price of ₹69.50 is trading 39.1% below its estimated GF Value™ of ₹114.08. GuruFocus considers Brooks Laboratories to be Significantly Undervalued.

Key valuation signals for BOM:533543:

  • Cyclically Adjusted Revenue per Share: ₹38.54
  • GF Value™: ₹114.08 vs. price of ₹69.50 (39.1% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Brooks Laboratories Business Description

Other Exchanges BROOKS:India
Address Near Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
59GF Score

Get the complete analysis for BOM:533543

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹69.50
Price
₹114.08
GF Value